Furthermore, TWEAK inhibition attenuated inflammatory responses by decreasing the activation of the NF-κB pathway and indirectly reducing the recruitment of macrophages to the kidney, which are known contributors to ADPKD inflammation and fibrosis. This evidence concerns the gene TNFSF12 and autosomal dominant polycystic kidney disease.